How does mirvetuximab soravtansine actually kill ovarian cancer cells?
Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) that binds to folate receptor alpha (FRα) on cancer cells, gets pulled inside, and releases a microtubule poison (DM4) that stops cell division and triggers cell death [1].
In the SORAYA trial, 36% of patients with platinum-resistant ovarian cancer had their tumors shrink or disappear, compared to just 13% on standard chemotherapy [2]. The drug works best when tumors have high FRα expression—75% or more of cancer cells must carry the target. This precision targeting means fewer healthy cells get harmed.
Once mirvetuximab soravtansine latches onto FRα, the cancer cell swallows it whole. Inside the cell, a protease enzyme cuts the linker, releasing DM4—a microtubule disruptor that freezes the cell's skeleton and triggers apoptosis (programmed cell death) [1]. Think of it as a Trojan horse: the antibody is the horse, and DM4 is the soldiers inside.
The trade-off is ocular toxicity. Because folate receptors also sit on healthy eye cells (corneal epithelium, lens, retina), DM4 can damage vision, causing keratopathy, dry eye, photophobia, and uveitis in 18–22% of patients [9]. Daily artificial tears and topical steroids, plus eye exams every other cycle for 8 cycles, catch problems early and prevent permanent blindness.
Ask your oncologist: 'Does my tumor have high FRα expression (≥75%)?' If yes, mirvetuximab soravtansine is worth the eye monitoring. If no, it won't work. Get a baseline eye exam and start artificial tears the day before your first infusion.